Other research analysts have also issued research reports about the stock. Jefferies Financial Group reduced their target price on shares of Indivior from GBX 250 ($3.27) to GBX 245 ($3.20) and set a buy rating on the stock in a research note on Thursday, October 11th. Citigroup reaffirmed a neutral rating on shares of Indivior in a research note on Monday, October 15th. Finally, Royal Bank of Canada lowered shares of Indivior to an outperform rating and reduced their price objective for the stock from GBX 350 ($4.57) to GBX 130 ($1.70) in a research note on Wednesday, November 21st. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. The company currently has an average rating of Hold and an average price target of GBX 234.40 ($3.06).
INDV traded down GBX 4.35 ($0.06) during midday trading on Tuesday, hitting GBX 103.05 ($1.35). The company had a trading volume of 2,105,411 shares, compared to its average volume of 2,440,000. Indivior has a twelve month low of GBX 246.50 ($3.22) and a twelve month high of GBX 436.60 ($5.70).
Indivior Company Profile
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, overdose rescue, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex.
See Also: What is Liquidity?
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.